Nestlé S.A. stock (CH0038863350): focus on 2025 slowdown and strategic vitamin review

Nestlé S.A. has reported lower results for the first half of 2025 and is reviewing parts of its vitamins-related activities, raising questions about growth momentum and margins for the global food group.

Nestlé S.A. has seen a setback in profitability in the first half of 2025 and has announced plans to intervene in parts of its vitamins-related operations, according to a report on Swiss trading platform Boursorama dated 07/18/2025 that summarizes comments by news agency ABM FN and outlines a decline in results alongside strategic portfolio considerations for the period.Boursorama as of 07/18/2025

As of: 20.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Nestlé
• Sector/industry: Packaged food and beverages
• Headquarters/country: Vevey, Switzerland
• Core markets: Global, with strong exposure to Europe, North America and emerging markets
• Key revenue drivers: Coffee, pet care, dairy and nutrition brands sold through retail and out-of-home channels
• Home exchange/listing venue: SIX Swiss Exchange (ticker: NESN); US OTC listing (NSRGY)
• Trading currency: Swiss franc on SIX; US dollar for ADRs

Nestlé S.A.: core business model

Nestlé S.A. is one of the world’s largest consumer food groups, generating most of its revenue from branded packaged goods such as coffee, pet food, infant nutrition, confectionery, dairy products and culinary items that are sold via supermarkets, discounters, e-commerce platforms and foodservice partners in more than 180 countries, according to the company’s own description.Nestlé company information as of 03/14/2025

The group’s business model rests on scale in manufacturing and distribution, global brand portfolios like Nescafé, Nespresso, Purina and KitKat, and a strategy aimed at premiumization and innovation to support pricing power, while continually adjusting its portfolio with acquisitions and divestitures to focus on categories and regions seen as more profitable over the long term.Nestlé investor materials as of 02/22/2025

In recent years Nestlé has emphasized categories with structural demand tailwinds such as coffee capsules, pet care and specialized nutrition, while exiting or reducing exposure to lower-margin or structurally challenged activities, a pattern that provides context for its ongoing review of vitamins-related operations following the weaker first-half 2025 performance reported in the ABM FN summary.

Main revenue and product drivers for Nestlé S.A.

In its recent financial communications for full-year 2024 published on 02/22/2025, Nestlé highlighted that its largest categories by sales include pet care, coffee, nutrition and dairy products, segments that together accounted for a majority of group revenue for the 2024 financial year, although the company did not break out exact percentages for each segment in the brief summary.Nestlé full-year 2024 press release as of 02/22/2025

The company reported organic growth in 2024 driven by pricing and a moderate contribution from volume and mix for the year ended 12/31/2024, according to its 2024 earnings release dated 02/22/2025, while underlying trading operating profit margin showed only limited expansion amid cost inflation, with management referencing continued efforts to improve efficiency and reinvest part of savings in marketing and product innovation.Nestlé results overview as of 02/22/2025

By geography, Nestlé generates significant sales in North America, Europe and emerging markets such as Latin America and Asia, with developed markets typically contributing stable cash flows and emerging markets adding faster unit growth; this diversification means that any slowdown in one region or product group, such as the vitamins-related businesses currently under review, is at least partially offset by other growth drivers.

Conclusion

The recent indication of lower results in the first half of 2025 and the review of vitamins-related activities underline that Nestlé S.A. is still navigating cost pressures and portfolio adjustments despite its broad diversification and strong brand portfolio, while full-year 2024 numbers showed resilient organic growth but only modest margin progress. For US investors following the ADR, the stock offers exposure to global consumer staples demand, but the combination of slower earnings momentum, strategic tweaks in health-related segments and currency factors suggests that close monitoring of upcoming trading updates, cost trends and capital allocation decisions will remain important for assessing the balance between stability and growth potential.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.